Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
10.44
+0.04 (0.38%)
At close: Apr 28, 2026, 4:00 PM EDT
10.43
-0.01 (-0.10%)
After-hours: Apr 28, 2026, 7:10 PM EDT
Telix Pharmaceuticals Revenue
In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 115.29% growth.
Revenue (ttm)
$803.79M
Revenue Growth
+55.61%
P/S Ratio
4.46
Revenue / Employee
$678,880
Employees
1,184
Market Cap
3.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Jan 1, 2024 | 332.98M | 224.17M | 206.01% |
| Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
| Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Catalyst Pharmaceuticals | 588.99M |
| Travere Therapeutics | 490.73M |
| Tango Therapeutics | 62.38M |
| NewAmsterdam Pharma Company | 22.50M |
| Crinetics Pharmaceuticals | 7.70M |
TLX News
- 1 day ago - Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - GlobeNewsWire
- 7 days ago - ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026 - GlobeNewsWire
- 13 days ago - Telix Pharma Doses First Patient In Phase 3 IPAX BrIGHT Trial Of TLX101-Tx; Prices $600 Mln Bonds - Nasdaq
- 14 days ago - Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma - GlobeNewsWire
- 14 days ago - Fundies feast on Telix Pharmaceuticals block amid $US550m convertible - The Australian Financial Review
- 15 days ago - Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Benzinga
- 15 days ago - Regeneron (REGN) Partners with Telix Pharmaceuticals - GuruFocus
- 15 days ago - Regeneron (REGN) Partners with Telix Pharmaceuticals for Innovative Radiopharmaceuticals - GuruFocus